Akero Corp (AKRO) - Long-Term Debt to Capital Coefficient

The historical price action of Akero Therapeutics (AKRO) demonstrates a metric of 0.00. The business focuses on developing treatments for liver pathologies, where patent control guarantees multi-year revenue. The development process utilizes AI and robotics, although final tests require medical supervision. Currently, the company is spending reserves on research and therefore needs to raise capital due to a temporary lack of profit.

An analysis of fundamental risks via the long-term debt-to-equity ratio allows for an assessment of the financial stability of Akero Therapeutics (AKRO) in the race for leadership in metabolic liver disease therapy. The current value of 0.00 within the long-term debt structure relative to equity determines the balance between bankruptcy protection and profitability, measuring the proportion of loans with a maturity of more than one year.